EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impact of p53 Target Genes on Drug Resistance in TP53 ‐Mutated B‐Cell Precursor Acute Lymphoblastic Leukemia

Thao T T Nguyen, Minori Tamai iD, Koshi Akahane iD, Chiaki Komatsu, Keiko Kagami, Xuekang Qi iD, Luay Aswad, Kunio Miyake iD, Shin Kasai iD, Shinpei Somazu iD, Atsushi Watanabe iD, Kumiko Goi und 12 weitere

Cancer Medicine · 2026

DOI: 10.1002/cam4.72386 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Thao T T Nguyen und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Tumor Suppressor Protein p53, Mutation, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, The Japanese Society of Hematology Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TP53 mutations are linked to poor prognoses in B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL), indicating that specific p53 target genes may contribute to drug resistance. Although the impact of specific genetic alterations on drug sensitivity has been reported in BCP‐ALL, the effects of TP53 mutations on sensitivity to individual agents remain poorly defined in the clinical setting because of the use of combination chemotherapy regimens. In the present study, we addressed this issue through two complementary analyses using a large panel of BCP‐ALL cell lines. Initially, 30 cell lines harboring TP53 mutations demonstrated significantly greater resistance to daunorubicin (DNR), mafosfamide (MAF; an active analog of cyclophosphamide), 6‐mercaptopurine (6‐MP), and prednisolone compared to 46 cell lines without mutations. Second, 11 CRISPR/Cas9‐mediated TP53 ‐knockout sublines derived from cell lines with wild‐type TP53 recapitulated resistance to DNR, MAF, and 6‐MP, as well as to vincristine (VCR) and cytarabine (Ara‐C). Consistent with these findings, re‐evaluation of genome‐wide CRISPR screening datasets revealed significant enrichment of TP53 gRNAs in cells treated with DNR, MAF, 6‐MP, Ara‐C, and VCR. Furthermore, transcriptomic and proteomic analyses of p53 target genes in the two cell line models, along with re‐evaluation of genome‐wide CRISPR screening datasets, identified BAX , BBC3 , and FDXR as key p53 target genes associated with multidrug resistance. These results highlight the potential value of targeting these p53 downstream pathways to improve outcomes in TP53 ‐mutated BCP‐ALL cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmTumor Suppressor Protein p53MutationPrecursor B-Cell Lymphoblastic Leukemia-LymphomaHumansCell Line, TumorDaunorubicinMercaptopurineVincristine

Stichwörter der Autor:innen

B‐cell precursor acute lymphoblastic leukemiaTP53 mutationcell linedrug resistancep53 target genes

Substanzen

Tumor Suppressor Protein p53TP53 protein, humanDaunorubicinMercaptopurineVincristine

Autor:innen und Institutionen

  • Department of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan.
  • Global Leukemia Cell-Line Assembly Network, University of Yamanashi, Chuo, Japan.
  • Clinical Proteomics Mass Spectrometry, Department of Oncology-Pathology, Karolinska Institutet, Science for Life Laboratory, Solna, Sweden.
  • Department of Epidemiology and Environmental Medicine, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Chuo, Japan.
  • Institute for Cancer Genetics, Columbia University, New York, New York, USA.
  • Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.

ORCID-Profile: Minori Tamai, Koshi Akahane, Xuekang Qi, Kunio Miyake, Shin Kasai, Shinpei Somazu, Atsushi Watanabe, Koichi Oshima, Hiroshi Imanaga, Yuichiro Semba, Hiroaki Goto, Takahiro Maeda, Rozbeh Jafari, Takeshi Inukai

Förderung

  • Japan Society for the Promotion of Science
  • The Japanese Society of Hematology Research

Zitieren

APA

Nguyen, T. T. T., Tamai, M., Akahane, K., Komatsu, C., Kagami, K., Qi, X., Aswad, L., Miyake, K., Kasai, S., Somazu, S., Watanabe, A., Goi, K., Oshima, K., Imanaga, H., Semba, Y., Sanada, M., Lehtiö, J., Goto, H., Minegishi, M., …, & Inukai, T. (2026). Impact of p53 Target Genes on Drug Resistance in TP53 ‐Mutated B‐Cell Precursor Acute Lymphoblastic Leukemia. Cancer Medicine. https://doi.org/10.1002/cam4.72386

Vancouver

Nguyen TTT, Tamai M, Akahane K, Komatsu C, Kagami K, Qi X, et al. Impact of p53 Target Genes on Drug Resistance in TP53 ‐Mutated B‐Cell Precursor Acute Lymphoblastic Leukemia. Cancer Medicine. 2026. doi:10.1002/cam4.72386

BibTeX
@article{Nguyen2026,
  author = {Nguyen, Thao T T and Tamai, Minori and Akahane, Koshi and Komatsu, Chiaki and Kagami, Keiko and Qi, Xuekang and Aswad, Luay and Miyake, Kunio and Kasai, Shin and Somazu, Shinpei and Watanabe, Atsushi and Goi, Kumiko and Oshima, Koichi and Imanaga, Hiroshi and Semba, Yuichiro and Sanada, Masashi and Lehtiö, Janne and Goto, Hiroaki and Minegishi, Masayoshi and Inaba, Toshiya and Iwamoto, Shotaro and Maeda, Takahiro and Jafari, Rozbeh and Inukai, Takeshi},
  title = {Impact of p53 Target Genes on Drug Resistance in TP53 ‐Mutated B‐Cell Precursor Acute Lymphoblastic Leukemia},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.72386}
}
Kostenlos starten →